会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE
    • 胰蛋白酶抑制剂化合物,它们的合成和用途
    • WO2003053944A1
    • 2003-07-03
    • PCT/US2002/041272
    • 2002-12-20
    • OSI PHARMACEUTICALS, INC.WITTER, DavidCASTELHANO, Arlindo, L.
    • WITTER, DavidCASTELHANO, Arlindo, L.
    • C07D265/12
    • C07D513/04A61K31/5365A61K31/542C07D333/38C07D409/12C07D498/02C07D513/02
    • The subject invention features compounds having the structure:, wherein X is O, S, CH 2 or NR 5 ; Y is O or S; R 1 is H, substituted or unsubstituted C 1 ­C 15 alkyl, C 1 -C 8 alkylaryl, -C(O)OR 4 , -C(O)NR 4 R 5 , -CR 6 R 6' OR 4 ,-CR 6 R 6' OC(O)R4, - CR 6 R 6' OC(O)NHR 7 , -C(O)NR 1o R 11 , -C(O)NR 8 R 9 NR 8 R 9 , -N(R 5 )C(O)NHR 5 , or CH 2 R 4 ; R 2 is a substituted or unsubstituted, straight chain C 1 -C 30 alkyl or branched C 3 C 30 alkyl, aryl, alkylaryl, arylalkyl, heteroarylalkyl or cycloalkyl; R 3 is H or substituted or unsubstituted C 1 -C 6 alkyl or C 3 -C 10 cycloalkyl; R 4 is H or a substituted or unsubstituted, straight chain or branched, C 6 -C 30 alkyl, aryl, -CH 2 -aryl, aryl -C 1 -C 15 alkyl, heteroaryl-C 1 -C 15 alkyl or C 3 -C 10 cycloalkyl; R 5 is H or a substituted or unsubstituted, straight chain or branched, C 6 -C 30 alkyl, aryl C 1 -C 30 alkyl, heteroarylalkyl or cycloalkyl; R 6 and R 6' are each independently H, substituted or unsubstituted C 1 -C 6 alkyl, dialkyl or C 3 -C 10 cycloalkyl or together form a 3-7 membered ring system; R 7 is H or substituted or unsubstituted C 1 -C 12 alkyl or C 3 -C 10 cycloalkyl; R 8 and R 9 are each independently H, substituted or unsubstituted C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylaryl, or NR 8 R 9 together form a substituted piperazine or piperidine ring or a dihydro-1H-isoquinoline ring system, or a specific enantiomer thereof, or a specific tautomer, or a pharmaceutically acceptable salt thereof and a method for treating diabetes or obesity by administering a therapeutically effective amount of the compounds of the invention.
    • 本发明的特征在于具有以下结构的化合物:其中X是O,S,CH 2或NR b 5; Y为O或S; R 1是H,取代或未取代的C 1 -C 15烷基,C 1至C 8 -C 8烷基 烷基芳基,-C(O)OR 4b,-C(O)NR b R 4,R 34,-CR sb, 6 OR 4 , - CR 6 ,-C(O)NR a R b,C(O)NR 7 R 8, -C(O)NR 8,R 9,R 9,R 8,R 9,R 9, ,-N(R 15)C(O)NHR 5或-SCH 2 R b R 4; R 2是取代或未取代的直链C 1 -C 30烷基或支链C 3 -C 30烷基或支链C 3〜 烷基,芳基,烷基芳基,芳基烷基,杂芳基烷基或环烷基; R 3是H或取代或未取代的C 1 -C 6烷基或C 3 -C 3 -C 4烷基。 10环烷基; R 4是H或取代或未取代的直链或支链的C 6 -C 15烷基,芳基,-CH 3 b, 芳基-C 1 -C 15烷基,杂芳基-C 1 -C 15烷基,芳基-C 1 -C 15烷基,杂芳基-C 1 -C 15烷基, sb>烷基或C 3 -C 30 -C 14环烷基; R 5是H或取代或未取代的直链或支链C 6 -C 15烷基,芳基C 1〜 烷基,杂芳基烷基或环烷基; R 6和R 6分别独立地为H,取代或未取代的C 1 -C 6烷基,二烷基 或C 3 -C 30烷基环烷基或一起形成3-7元环系; R 7是H或取代或未取代的C 1 -C 12烷基或C 3 -C 3 - 烷基。 10环烷基; R 8和R 9各自独立地为H,取代或未取代的C 1 -C 6烷基,C 6 - 烷基,C 1 -C 6烷基芳基或NR b 8烷基, 一起形成取代的哌嗪或哌啶环或二氢-1H-异喹啉环体系或其特定的对映体或其互变异构体或其药学上可接受的盐和糖尿病治疗方法 或肥胖,通过施用治疗有效量的本发明化合物。